Stevens-Johnson syndrome
Stevens-Johnson syndrome
Explore linked clinical trials. Standard reference: MONDO:00182296 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Subconjunctival Humira for Boston Keratoprosthesis | Chemically-Induced Disorders, Conjunctival Diseases, Drug Eruptions, Drug-Related Side Effects and Adverse Reactions, Erythema, Hypersensitivity, Delayed, Pemphigoid, Benign Mucous Membrane, Skin and Connective Tissue Diseases, Stevens-Johnson syndrome, Stomatognathic Diseases, dermatitis, drug allergy, erythema multiforme, eye disorder, immune system disorder, mouth disorder, ocular cicatricial pemphigoid, skin disorder, stomatitis, vesiculobullous skin disease | Not yet recruiting | Phase 1 | 2026-08-31 | NCT06926478 | |
| HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness | Arthritis, Gouty, Chemically-Induced Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Crystal Arthropathies, Drug Eruptions, Drug-Related Side Effects and Adverse Reactions, Erythema, Hypersensitivity, Delayed, Hyperuricemia, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Stevens-Johnson syndrome, Stomatognathic Diseases, arthritic joint disease, arthropathy, dermatitis, drug allergy, erythema multiforme, gout, hereditary disease, immune system disorder, inborn disorder of purine or pyrimidine metabolism, inborn errors of metabolism, metabolic disease, mouth disorder, musculoskeletal system disorder, rheumatic disorder, skin disorder, stomatitis, vesiculobullous skin disease | Not yet recruiting | Phase 4 | 2026-01-27 | NCT07369622 | |
| New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies. | Chemically-Induced Disorders, Drug Eruptions, Drug-Related Side Effects and Adverse Reactions, Erythema, Hypersensitivity, Delayed, Skin and Connective Tissue Diseases, Stevens-Johnson syndrome, Stomatognathic Diseases, dermatitis, drug allergy, erythema multiforme, immune system disorder, mouth disorder, skin disorder, stomatitis, vesiculobullous skin disease | Not yet recruiting | Phase 1 / Phase 2 | 2025-08-07 | NCT07110662 | |
| LYell SYndrome MEsenchymal Stromal Cells Treatment | Chemically-Induced Disorders, Drug Eruptions, Drug-Related Side Effects and Adverse Reactions, Erythema, Hypersensitivity, Delayed, Skin and Connective Tissue Diseases, Stevens-Johnson syndrome, Stomatognathic Diseases, dermatitis, drug allergy, erythema multiforme, immune system disorder, mouth disorder, skin disorder, stomatitis, vesiculobullous skin disease | Recruiting | Phase 1 / Phase 2 | 2025-08-01 | NCT04711200 | |
| Autologous Serum Obtained by a Closed-Circuit Collection Device | Chemically-Induced Disorders, Drug Eruptions, Drug-Related Side Effects and Adverse Reactions, Erythema, Hypersensitivity, Delayed, Meibomian Gland Dysfunction, Skin and Connective Tissue Diseases, Stevens-Johnson syndrome, Stomatognathic Diseases, dermatitis, drug allergy, erythema multiforme, eye disorder, eyelid disorder, graft versus host disease, immune system disorder, mouth disorder, skin disorder, stomatitis, vesiculobullous skin disease | Not yet recruiting | Phase 2 | 2025-06-10 | NCT07014059 | |
| Drug Reactions Sampling (COLLECTIONTOXIDERMIES) | Chemically-Induced Disorders, Drug Eruptions, Drug-Related Side Effects and Adverse Reactions, Erythema, Fibrosis, Hypersensitivity, Delayed, Morbilliform Drug Reaction, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Stevens-Johnson syndrome, Stomatognathic Diseases, acute generalized exanthematous pustulosis, dermatitis, drug allergy, drug rash with eosinophilia and systemic symptoms, erythema multiforme, immune system disorder, mouth disorder, severe cutaneous adverse reaction, skin disorder, stomatitis, vesiculobullous skin disease | Recruiting | Not stated | 2022-05-03 | NCT03659227 |